Talecris, a Ludicrously Large IPO, and the Beginning of the End for Private Equity?
Editor’s note: This article is reprinted with permission of VentureBeat. David Hamilton writes about life sciences for VentureBeat. Talecris filed for an IPO on July 27. Is the air starting to hiss out of the private-equity bubbble? Looking at Talecris Biotherapeutics – a stodgy biotech controlled by private-equity firms Cerberus Capital Management and Ampersand Ventures that filed to raise as much as $1 billion in an initial offering – you’d be perfectly justified in thinking so. For starters, the IPO is just ridiculously huge. Biotech offerings that raise more than $100 million are fairly rare; this year, for instance, only three...
Read More
